CAClare Arnott

Clare Arnott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clare Arnott has a total of 418 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring Predictive Modeling Algorithms for Good Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Secondary Analysis of a Cluster Randomized Trial Cohort Further Explored by Sex

    by Sana Shan, Antonio Michell, Angela Xun‐Nan Chen, Anthony Devaux, Clare Arnott, Laurent Billot, Anna Campain, Uday Adavi, Rimma Myton, Integrate Team, et al.

    Background and Aims: Predictive modeling algorithms show promise in identifying risk factors influencing clinical outcomes. This study aims to evaluate different machine learning algorithms to identify an accurate predictive model of glycemic control at 18‐months follow‐up in type 2 diabetes mellitus (T2DM) patients and explore sex‐specific risk factors. Methods: Data of T2DM patients from the INTEGRATE dataset (2016–2019) were used. Baseline demographic, anthropometric, clinical biomarkers, and Charlson Comorbidity Index (CCI) were included to develop predictive models using LASSO logistic regression, CART, XGBoost, and Random Forest. Model discrimination was assessed using the area under the curve (AUC), calibration using calibration intercept, slope, and Brier score, clinical utility using decision‐curve analysis (DCA), and model interpretability using SHapley Additive exPlanations (SHAP). Sex‐specific predictors were identified by training separate LASSO models independently within each sex stratum. Results: Participants ( n = 4821) had a mean age of 65.4±12.8 years, BMI of 31.4 ± 6.7 kg/m 2 , and 46.6% were female. The predictive models had an AUC of 0.68–0.71, with broadly acceptable calibration across all models. Decision‐curve analysis demonstrated net benefit over treat‐all and treat‐none strategies across clinically plausible threshold probabilities (10%–50%). Insulin use was the strongest predictor of poor glycemic control (HbA1c ≥ 7.0%) in both sexes (males: −2.46, 95% CI: −2.91 to −1.96; females: −2.10, 95% CI: −2.67 to −1.64). SHAP analysis confirmed diabetes medication intensity as the dominant predictor. Sex‐specific predictors included higher HDL in males, and severe comorbidity index in females, although estimates were imprecise. Conclusion: LASSO logistic regression and XGBoost showed the highest discrimination (AUC: 0.71) with broadly acceptable calibration. Decision‐curve analysis supported clinical utility across plausible threshold probabilities. SHAP analysis confirmed diabetes medication intensity as the dominant predictor, consistent with sex‐stratified findings. External validation in independent cohorts remains necessary before clinical implementation.

  • Open Access

    Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: insights from the CREDENCE trial

    by Emily K Yeung, Amanda Siriwardana, Luke Buizen, Arthur H C Tang, Min Jun, Kevan R Polkinghorne, Sydney C W Tang, Sradha Kotwal, Clare Arnott, Adeera Levin, et al.

    Background: Polypharmacy in chronic kidney disease (CKD) is substantial. Clinicians and patients are often reluctant to add medications to already complex regimens, partly due to concerns about diminishing efficacy and increased adverse effects. We assessed whether the efficacy and safety of canagliflozin are modified by polypharmacy status in patients with type 2 diabetes (DM) and CKD. Methods: We conducted a post-hoc analysis of the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial, which evaluated the effects of canagliflozin on outcomes in patients with DM and CKD. Participants were categorized as no polypharmacy (0–4 medicines), polypharmacy (5–9 medicines) or hyperpolypharmacy (≥10 medicines). We assessed the relative effects of canagliflozin on clinical and safety outcomes by polypharmacy status using Cox proportional hazards models. We assessed absolute benefits using Poisson regression. The primary outcome was a composite of doubling of serum creatinine, kidney failure, or death due to cardiovascular or kidney disease. Results: Among 4401 participants, 612 (14%), 2404 (55%) and 1385 (31%) were categorized as no polypharmacy, polypharmacy and hyperpolypharmacy, respectively. Mean number of medications was 8.3 (SD 3.77). The effect of canagliflozin on kidney and cardiovascular outcomes was consistent irrespective of polypharmacy status, with no interaction observed for safety outcomes (all P-interaction >.06). Rates of treatment discontinuation increased with medication burden, but were lower with canagliflozin versus placebo, regardless of polypharmacy status (P-interaction = .16). Incidence of all-cause hospitalization, and heart failure hospitalization or cardiovascular death increased with higher medication burden; thus absolute risk reductions were estimated to be substantially greater in patients with polypharmacy and hyperpolypharmacy. Conclusion: Among patients with DM and CKD, the efficacy and safety of canagliflozin appear consistent regardless of polypharmacy status, with larger estimated absolute reductions in hospitalizations and cardiovascular events in those experiencing polypharmacy or hyperpolypharmacy. These findings suggest that polypharmacy alone should not preclude consideration of sodium glucose cotransporter 2 inhibitor therapy in patients with CKD and DM for whom treatment is otherwise indicated.

  • Open Access

    Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy on CKD progression

    by Hiddo J L Heerspink, Clare Arnott, Jonathan Barratt, Kirk N Campbell, Roberto Pecoits-Filho, Kei Fukami, Jean-Michel Halimi, Fan Fan Hou, Carolyn S P Lam, Adeera Levin, et al.

    Background: A low dose of the selective endothelin A receptor antagonist zibotentan in combination with the sodium−glucose co-transporter 2 inhibitor dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) by ∼30% compared with dapagliflozin alone in a phase 2b study without increasing the risk of fluid retention. These findings supported the design and conduct of the ZENITH High Proteinuria trial (NCT06087835) to assess the long-term efficacy and safety of a fixed-dose combination zibotentan/dapagliflozin in delaying the progression of chronic kidney disease (CKD). Methods: ZENITH High Proteinuria is an ongoing randomized, double-blind, placebo-controlled phase 3 trial enrolling participants with CKD [defined as UACR >700 mg/g or urinary protein-to-creatinine ratio >1000 mg/g and estimated glomerular filtration rate (eGFR) ≥20–<90 ml/min/1.73 m2] with and without type 2 diabetes. Eligible participants were randomized 1:1 to zibotentan/dapagliflozin 0.25/10 mg (if eGFR<45 ml/min/1.73 m2)/0.75/10 mg (if eGFR ≥45 ml/min/1.73 m2) or placebo/dapagliflozin on top of standard of care, including maximum tolerated renin–angiotensin-system blockade. The primary efficacy outcome is the mean eGFR change from baseline to Month 24. Secondary efficacy outcomes include time to the composite of end-stage kidney disease, sustained ≥40% decrease in eGFR, or renal death. Adverse events are collected to assess safety. Results: Participants were enrolled from November 2023 to November 2024 from 30 countries. Overall, 2910 patients were screened, of whom 1833 were randomized and treated. Mean age at baseline was 61 years and 28% were female. Mean (standard deviation) eGFR was 44.0 (18.2) ml/min/1.73 m2, median (interquartile range) UACR was 1262 (801–2097) mg/g, and median (interquartile range) B-type natriuretic peptide was 44 (23–86) ng/l. Conclusion: To evaluate the effect of zibotentan and dapagliflozin combination therapy, the ZENITH High Proteinuria study has successfully recruited a population at high risk of CKD progression for whom novel therapies remain necessary. Results are expected in 2027.


  • Open Access

    Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

    by Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, et al.

    Aims: GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines remains poorly quantified. Methods: We used national pharmaceutical sales data to quantify population use of GLP‐1 medicines listed for T2D in Australia, May 2020–April 2025. We used Pharmaceutical Benefits Scheme (PBS) dispensing claims to measure subsidized access; we estimated private access as the difference between sales and PBS dispensings. We measured GLP‐1 medicine use as number of units sold/dispensed and defined daily dose (DDD)/1000 population/day. Results: Since May 2020, total sales of GLP‐1 medicines indicated for T2D increased almost 10‐fold. Most growth was in private access, driven by semaglutide and rapid uptake of tirzepatide. Supply dropped by 79% during periods of global shortage and primarily accessed through subsidized care. In the year May 2024–April 2025, the majority of GLP‐1 medicines used were semaglutide (63.3%) and tirzepatide (30.7%). Half (47.8%) were accessed privately (26.9% of semaglutide; all tirzepatide). In this year, we estimate approximately 483 000–502 000 people accessed GLP‐1 medicines each month, with 180 000–240 000 people accessing privately. Conclusions: Use of GLP‐1 medicines indicated for T2D has increased dramatically, accessed by approximately half a million Australians each month, almost half of which is private. Our findings highlight demands outside of subsided care, equity concerns for access and pressures for health systems in meeting this demand.


  • Open Access

    Patient perspectives on cardioprotective medication during breast cancer treatment

    by Lauren Houston, Nusayba A. Bagegni, Mei Ling Yap, Elgene Lim, Bruce Neal, Anita Deswal, Joshua D. Mitchell, Clare Arnott, Sang Gune K. Yoo

    Background: Cardiotoxicity remains a key concern of HER2-directed therapies, with no proven prevention strategies. The success of cardioprotective interventions will depend not only on efficacy, but on patient acceptability, an underexplored determinant of trial participation and clinical implementation. Objectives: To evaluate willingness to take cardioprotective medication and identify factors influencing decision-making among individuals with HER2-positive breast cancer. Methods: We conducted a cross-sectional online survey of adults with HER2-positive breast cancer in Australia and the United States. The survey assessed willingness, beliefs regarding benefits and risks, and treatment preferences. Multivariable logistic regression examined associations between clinical and demographic characteristics and willingness. Results: Among 74 respondents (Australia n=24; United States n=50), 74.3% reported being likely or very likely to take cardioprotective medication. Physician recommendation emerged as a dominant driver (79.1%). While most participants valued long-term cardiovascular health (72.9%), uncertainty regarding benefit was common (60.4%). Cancer-related outcomes were prioritized over cardiovascular outcomes. Participants demonstrated flexibility regarding treatment burden, including willingness to take multiple medications and continue therapy long-term. No demographic or clinical predictors of willingness were identified. Perceived acceptability, appropriateness, and feasibility were consistently high. Conclusions: Willingness to adopt cardioprotective strategies is high but conditional, shaped by cancer priorities, clinician endorsement, and uncertainty regarding benefit. These findings highlight patient acceptability as a critical, and often overlooked, determinant of successful trial participation and downstream clinical implementation in cardio-oncology.

  • Open Access

    A novel deep learning-based grading system for assessing breast arterial calcification on mammograms, as an independent risk factor for predicting adverse cardiovascular events

    by Mu’ATh Ibrahim, Patrick C. Brennan, Mo’AYyad E. Suleiman, Mary Rickard, Clare Arnott, Jennifer Y. Barraclough, Seyedamir Tavakoli Taba, Ziba Gandomkar

    Purpose: To develop a deep learning-based framework for automated detection and grading of breast arterial calcification (BAC) on mammograms, and to evaluate its association with major adverse cardiovascular events (MACE). Material and methods: This retrospective case–control study used two datasets: SegModel (1270 mammograms with BAC annotations) and MACEPred (3190 mammographic cases of women with MACE, plus 6458 controls). A U-Net segmentation model and Cox proportional hazards models were used to assess adjusted hazard ratios (HRs) for four BAC grading strategies: binary categorization, area-based grading (none, mild, moderate, severe), intensity-based grading, and a combined approach. Findings: The U-Net attained a Jaccard similarity coefficient of 0.582, accuracy of 0.996, precision of 0.801, F1 score of 0.756, and recall of 0.716 in segmenting BAC. The presence of BAC was associated with an adjusted HR of 1.16 (95% CI 1.10–1.23). For area-based grading, the HRs for mild, moderate, and severe grades were 1.13 (95% CI 1.06–1.20), 1.30 (95% CI 1.18–1.45), and 1.58 (95% CI 1.15–2.18), respectively. Intensity-based grading showed respective HRs of 1.08 (95% CI 1.00–1.17), 1.10 (95% CI 1.01–1.20), and 1.18 (95% CI 1.09–1.28). The combined approach demonstrated respective HRs of 1.102 (95% CI 1.04–1.17), 1.249 (95% CI 1.14–1.37), and 1.654 (95% CI 1.30–2.10) for mild, moderate, and severe grades. Conclusion: Our study presents a novel automated framework for BAC assessment that provides independent insights into cardiovascular risk in women. Combined area and intensity grading reflected increasing MACE risk across BAC severity levels, although its incremental predictive improvement was limited.

  • Regional fat distribution as a determinant of mortality in populations with left ventricular systolic dysfunction: challenging the obesity paradox

    by Shaun Khanna, William Ho, Fumihiko Takeuchi, Cheng Hwee Soh, Aditya Bhat, Andrew Lin, Anushka Patel, Liza Thomas, Thomas H Marwick, Nitesh Nerlekar, et al.

    Aims: Obesity and regional fat distribution are associated with adverse cardiovascular outcomes, yet the prognostic significance of specific adiposity phenotypes in individuals with left ventricular systolic impairment remains incompletely defined. Body mass index (BMI) incompletely captures fat distribution and may underestimate metabolically adverse adiposity. Methods and results: Participants from the community-based UK Biobank Imaging Enhancement Programme who underwent cardiac magnetic resonance (CMR) imaging were evaluated. Individuals with CMR-defined left ventricular systolic impairment [left ventricular ejection fraction <50%] were identified, while participants with prevalent heart failure at baseline were excluded. Adiposity was assessed using BMI, waist circumference (WC), waist-to-hip ratio (WHR), body fat percentage, and total fat mass. Associations between adiposity measures (per 1 SD increase) and all-cause and cardiovascular (CV) mortality were evaluated using Cox proportional hazards models adjusted for age, sex, hypertension, diabetes mellitus, hypercholesterolaemia, and smoking. Left ventricular (LV) impairment aetiology was classified as ischaemic or non-ischaemic using International Classification of Diseases, 10th Revision codes or self-reported prior myocardial infarction. All analyses were performed using R 4.4.0 within the UK Biobank Research Analysis Platform. Among 5615 participants with CMR-defined LV systolic impairment (mean age 56.7 ± 7.4 years; 52% male), 290 all-cause and 76 CV deaths occurred over a median follow-up of 13.5 years. In fully adjusted analyses, BMI was associated with increased all-cause [hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.05–1.34] and CV mortality (HR 1.37, 95% CI 1.11–1.69). Central adiposity measures demonstrated stronger associations with outcomes, particularly WC (all-cause HR 1.25; CV HR 1.49) and WHR (all-cause HR 1.30; CV HR 1.52). Compared with a BMI-based reference model (C-statistic 0.67 for all-cause and 0.71 for CV mortality), inclusion of WC and WHR resulted in modest but statistically significant improvements in discrimination (ΔC up to +0.008 for all-cause and +0.012 for CV mortality), whereas general adiposity measures, including body fat percentage and total fat mass, did not meaningfully improve incremental discrimination. Conclusion: In this large imaging-defined cohort of individuals with LV systolic impairment, central adiposity measures, particularly WC and WHR, were more strongly associated with CV mortality than BMI, body fat percentage, or total fat mass. These findings suggest that fat distribution, rather than overall adiposity alone, provides important prognostic information in individuals with LV systolic impairment. Registration: Biobank Project ID 55469


  • Open Access

    Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk

    by Phyo Pyae Nyein, Hila Haskelberg, Marianne Martinello, Margaret Lowe, David Goodman-Meza, Anchalee Avihingsanon, Anthony D. Kelleher, Anthony Rodgers, Aletta E. Schutte, Eriobu Chukwudalu Nnakelu, et al.

    People with HIV have an increased cardiovascular disease (CVD) risk due to both HIV and adverse effects of treatments. The currently preferred class of anti-retroviral drugs, integrase strand transfer inhibitors (INSTIs), has variably been linked to higher CVD risk and weight gain. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce CVD events and heart failure hospitalisations in people with or without type 2 diabetes, while also reducing weight and blood pressure, but have not been studied in people with HIV. Pitavastatin lowers CVD events in those with HIV, although it is not widely available. OPTIMAR is a 2 × 2 factorial, randomised, placebo-controlled, double-blind, phase III/IV trial and will examine the efficacy and safety of dapagliflozin 10 mg versus placebo on metabolic parameters and of rosuvastatin 10 mg + ezetimibe 10 mg versus pitavastatin 4 mg. A cardiac substudy will determine the effect of dapagliflozin versus placebo on epicardial adipose tissue (EAT) volume and coronary plaque characteristics. Virologically suppressed individuals with HIV on INSTI-based ART aged 40-75 years who had a significant weight gain after starting INSTI or BMI ≥ 30 kg/m2 will be included. Participants will be randomised 1:1 to blinded dapagliflozin or placebo, followed by 1:1 to open-label rosuvastatin + ezetimibe or pitavastatin for 48 weeks. The primary endpoints will be body weight and LDL reduction for the SGLT2i and statin randomisations respectively in the modified intention-to-treat population. Follow-up will continue to 48 weeks with primary analysis at week-24 and follow-up analysis at week-48. OPTIMAR is the first trial to investigate the use of SGLT2i as a cardiometabolic intervention in people with HIV. Demonstrating favourable cardiometabolic effects of SGLT2i will introduce an innovative approach to primary CVD prevention in this at-risk population and support conducting larger trials evaluating clinical endpoints including major adverse cardiovascular events. If the combination of rosuvastatin and ezetimibe is found to be similar or superior to pitavastatin, this will inform a more feasible lipid management approach for people with HIV internationally, especially in resource-limited settings. The cardiac sub-study will further clarify the cardioprotective role of SGLT2i and provide mechanistic insights. ClinicalTrials.gov, NCT06317051 (https://clinicaltrials.gov/study/NCT06317051?cond=HIV&intr=Dapagliflozin&aggFilters=status:not%20rec&rank=2). Registration on 21 February 2024.